04/29/10
CG3 Attending American Association of Thoracic Surgeons Meeting in Toronto May 2-4, 2010
Patrick Kullmann, CG3 Consulting to attend AATS meeting to work in the eHealth Medical space for cardiac health care and wellness company www.iMobilewellness.com.
04/27/10
CG3 Consulting Continues to Expand Venture Capital Support and Advisory Role in Life Science Markets
CG3 Minneapolis, Boston and San Deigo continues to serve the investment community by providing screening and due diligence support and other investment advisory services in the life science area to experienced life science venture and angel firms as well as general venture capital and angel firms with little or no experience in the life science areas.
04/27/10
AstraZeneca PLC, in a settlement with the U.S. Justice Department, agreed to pay about $520 million
AstraZeneca PLC, in a settlement with the U.S. Justice Department, agreed to pay about $520 million See: http://bit.ly/aPSXe3
04/25/10
Merck Discloses Health-Overhaul Costs See Story at : http://bit.ly/cfHai9
Merck & Co. said Friday that the recently enacted U.S. health-care overhaul legislation would reduce its revenue by $170 million this year and up to $350 million next year, but the drug maker reaffirmed its long-term profit forecast.
04/25/10
FDA Planning More Regulation Of Drug-Infusion Pumps: See http://bit.ly/b3PxYT
The FDA cited an increase in the number and severity of problems with external infusion pumps. It said it has received 56,000 reports of problems in the past five years, including more than 500 deaths associated with the devices.
04/22/10
FDA Pushes Oversight of Devices - http://bit.ly/btoUxN
The Food and Drug Administration is raising a red flag, calling for greater oversight of devices such as dialysis machines, ventilators, infusion pumps and IV machines—which are increasingly operated by patients, family members and other minimally trained caregivers.
04/20/10
Pharma Sales Set to Grow 5%-8%; Overhaul Effects Unclear Following Healthcare Reform
Already pharma companies are changing their sales and earnings expectations because of legislative changes that take place immediately, such as increased Medicaid rebates. Johnson & Johnson today said changes to the U.S. system would pare 2010 earnings by about 10 cents a share and cut revenue by between $400 million and $500 million.
04/06/10
CG3 Consulting Working with Physician Inventors of Medical Devices-For Acquisition, Funding & Growth
CG3 Consulting is working with physician inventors in the process of bringing new medical devices to market. CG3 is a partner that stays abreast of current industry news and can anticipate many of the requirements that will allow physicians to introduce their products successfully. We support medical device and other medical technology inventors prepare their products for presentations to potential inventors, acquirers or to build a sustainable growth medical device company. Located in Minneapolis, Boston and San Diego.
